GlassScriptPhysician profile
Aung Bajaj
NPI 1598177255
$16,644.47
in general payments reported to CMS, 2019-2025
66 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $211 · 2021: $224 · 2022: $2,384 · 2023: $6,064 · 2024: $4,390 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,427 · Consulting Fee: $3,975 · Education: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,427.49 |
| Consulting Fee | $3,975.00 |
| Education | $980.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,860.19 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Taiho Oncology, INC. | $1,497.51 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $1,000.94 | 2022-2025 | Opdivo |
| Celgene Corporation | $809.09 | 2019-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $769.76 | 2022-2025 | |
| Beigene USA, INC. | $731.72 | 2022-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $607.72 | 2020-2025 | Lynparza, Imfinzi, Enhertu |
| Pfizer INC. | $600.82 | 2019-2025 | |
| Incyte Corporation | $475.35 | 2019-2025 | Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $432.42 | 2019-2025 | |
| Astellas Pharma US INC | $421.57 | 2019-2024 | Vyloy, Xospata |
| Amgen INC. | $378.90 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Genzyme Corporation | $343.93 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $341.04 | 2023-2025 | Orgovyx |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $282.59 | 2023-2024 | Krazati |
| Gilead Sciences, INC. | $274.23 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $269.43 | 2022-2025 | Polivy, Lunsumio, Phesgo |
| Abbvie INC. | $267.76 | 2023-2025 | Lupron Depot, Venclexta |
| Glaxosmithkline, LLC. | $202.28 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $200.54 | 2023-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $196.16 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Genmab U.S., INC. | $193.50 | 2023-2025 | Epkinly, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $188.18 | 2019-2024 | Ninlaro, Fruzaqla, Vpriv |
| Eisai INC. | $184.70 | 2022-2024 | |
| Array Biopharma INC | $170.15 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Aveo Pharmaceuticals, INC. | $169.00 | 2023-2024 | Fotivda |
| Seagen INC. | $158.35 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Apellis Pharmaceuticals, INC. | $140.74 | 2022-2023 | Empaveli |
| Dova Pharmaceuticals | $139.02 | 2019 | |
| Lilly USA, LLC | $133.03 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $132.87 | 2020-2025 | Libtayo |
| Blueprint Medicines Corporation | $120.96 | 2022-2024 | Ayvakit |
| Sobi, INC | $108.60 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $91.98 | 2022-2025 | Monoferric |
| Springworks Therapeutics, INC. | $85.09 | 2024-2025 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $83.61 | 2022-2024 | Ultomiris |
| Stemline Therapeutics INC. | $82.64 | 2019-2023 | Orserdu |
| Kite Pharma, INC. | $75.60 | 2022-2024 | Yescarta |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Kyowa Kirin, INC. | $68.97 | 2022-2024 | Poteligeo |
| Exelixis INC. | $58.73 | 2023-2024 | Cabometyx |
| Jazz Pharmaceuticals INC. | $58.68 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $54.30 | 2019-2024 | Tavalisse, Rezlidhia |
| Myovant Sciences INC. | $53.77 | 2021-2022 | |
| Cti Biopharma Corp. | $53.12 | 2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $47.74 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $47.60 | 2022-2023 | Imbruvica |
| Puma Biotechnology, INC. | $44.95 | 2023-2025 | Nerlynx |
| Sun Pharmaceutical Industries INC. | $36.32 | 2023 | Odomzo, Yonsa |
| Pharmaessentia USA Corporation | $36.02 | 2022-2024 | Besremi |
| Karyopharm Therapeutics INC. | $33.31 | 2024 | Xpovio |
| Janssen Pharmaceuticals, INC | $29.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2023 | Gilotrif |
| Alnylam Pharmaceuticals INC. | $24.80 | 2023 | Givlaari |
| Adc Therapeutics America, INC. | $24.09 | 2024 | |
| Dendreon Pharmaceuticals LLC | $18.95 | 2022 | |
| Emd Serono, INC. | $18.05 | 2023 | Tepmetko |
| Verity Pharmaceuticals INC. | $17.78 | 2023 | Trelstar |
| Morphosys, US INC. | $17.48 | 2023 | Monjuvi |
| Aurobindo Pharma USA, INC. | $17.08 | 2019 | |
| Adaptive Biotechnologies Corporation | $14.08 | 2024 | Clonoseq |
| G1 Therapeutics, INC. | $13.34 | 2022 | |
| Verastem, INC. | $12.06 | 2020 | |
| Heron Therapeutics, INC. | $10.87 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aung Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.